Radiopharm Theranostics Ltd (RAD) - Net Assets
Based on the latest financial reports, Radiopharm Theranostics Ltd (RAD) has net assets worth AU$42.87 Million AUD (≈ $30.33 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$86.48 Million ≈ $61.19 Million USD) and total liabilities (AU$43.61 Million ≈ $30.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read RAD liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$42.87 Million |
| % of Total Assets | 49.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 42.98 |
Radiopharm Theranostics Ltd - Net Assets Trend (2021–2025)
This chart illustrates how Radiopharm Theranostics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore RAD asset base for the complete picture of this company's asset base.
Annual Net Assets for Radiopharm Theranostics Ltd (2021–2025)
The table below shows the annual net assets of Radiopharm Theranostics Ltd from 2021 to 2025. For live valuation and market cap data, see RAD company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$42.87 Million ≈ $30.33 Million |
+56.73% |
| 2024-06-30 | AU$27.35 Million ≈ $19.35 Million |
-39.99% |
| 2023-06-30 | AU$45.58 Million ≈ $32.25 Million |
-27.61% |
| 2022-06-30 | AU$62.96 Million ≈ $44.55 Million |
+50590.14% |
| 2021-06-30 | AU$-124.70K ≈ $-88.24K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Radiopharm Theranostics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14524776200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$176.56 Million | 394.17% |
| Other Comprehensive Income | AU$13.97 Million | 31.18% |
| Total Equity | AU$44.79 Million | 100.00% |
Radiopharm Theranostics Ltd Competitors by Market Cap
The table below lists competitors of Radiopharm Theranostics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jeongsan Aikang Co.Ltd
KQ:022220
|
$31.38 Million |
|
Gold Strike Resources Corp.
V:GSR
|
$31.38 Million |
|
Duc Long Gia Lai Group JSC
VN:DLG
|
$31.39 Million |
|
Sentronic International
TWO:3232
|
$31.40 Million |
|
KB Autosys Co. Ltd
KQ:024120
|
$31.37 Million |
|
KH Group Oyj
HE:KHG
|
$31.36 Million |
|
Seafire AB
ST:SEAF
|
$31.35 Million |
|
Daeho Al Co. Ltd.
KO:069460
|
$31.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Radiopharm Theranostics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,122,562 to 44,792,004, a change of 16,669,442 (59.3%).
- Net loss of 36,703,089 reduced equity.
- Share repurchases of 53,977,900 reduced equity.
- New share issuances of 53,977,902 increased equity.
- Other comprehensive income decreased equity by 24,813,153.
- Other factors increased equity by 78,185,682.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-36.70 Million | -81.94% |
| Share Repurchases | AU$53.98 Million | -120.51% |
| Share Issuances | AU$53.98 Million | +120.51% |
| Other Comprehensive Income | AU$-24.81 Million | -55.4% |
| Other Changes | AU$78.19 Million | +174.55% |
| Total Change | AU$- | 59.27% |
Book Value vs Market Value Analysis
This analysis compares Radiopharm Theranostics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.88x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | AU$0.00 | AU$0.02 | x |
| 2022-06-30 | AU$0.23 | AU$0.02 | x |
| 2023-06-30 | AU$0.14 | AU$0.02 | x |
| 2024-06-30 | AU$0.07 | AU$0.02 | x |
| 2025-06-30 | AU$0.02 | AU$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Radiopharm Theranostics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -81.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -273.90%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.93x
- Recent ROE (-81.94%) is below the historical average (-75.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-472.72K |
| 2022 | -48.19% | -343550.89% | 0.00x | 1.32x | AU$-36.64 Million |
| 2023 | -77.98% | -11838.59% | 0.00x | 1.69x | AU$-39.05 Million |
| 2024 | -170.50% | -16024.28% | 0.00x | 2.56x | AU$-50.76 Million |
| 2025 | -81.94% | -273.90% | 0.15x | 1.93x | AU$-41.18 Million |
Industry Comparison
This section compares Radiopharm Theranostics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $13,951,937
- Average return on equity (ROE) among peers: -63.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Radiopharm Theranostics Ltd (RAD) | AU$42.87 Million | 0.00% | 1.02x | $31.38 Million |
| Adalta Ltd (1AD) | $5.38 Million | -112.69% | 0.98x | $8.12 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $5.53 Million | -110.79% | 0.18x | $20.04 Million |
| ACRUX Ltd (ACR) | $43.92 Million | -0.55% | 0.08x | $3.49 Million |
| Actinogen Medical Ltd (ACW) | $15.66 Million | -63.12% | 0.04x | $103.45 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $8.35 Million | -58.19% | 0.43x | $66.62 Million |
| Anatara Lifesciences Ltd (ANR) | $3.83 Million | -52.11% | 0.13x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $30.47 Million | -50.24% | 0.10x | $80.80 Million |
| Amplia Therapeutics Ltd (ATX) | $9.77 Million | -46.00% | 0.04x | $54.45 Million |
| Avecho Biotechnology Ltd (AVE) | $2.65 Million | -99.27% | 0.26x | $31.19 Million |
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more